|
[1] Loong TH, Soon NC, Nik M, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus [J]. Biomed Rep, 2017, 7(5):460-468. [2] 中华医学会消化病分会. 中国慢性胃炎共识意见(2017年,上海)[J]. 中华消化杂志, 2017, 37(11): 721-738. [3] 刘莉. 健脾益胃汤联合抗H.pylori疗法对脾胃虚弱型CAG胃黏膜萎缩影响的临床研究[D]. 黑龙江中医药大学, 2008. [4] 刘文忠. 重视对胃黏膜萎缩和肠化生的研究[J]. 中华消化杂志, 2003, 23(3):135-136. [5] 李兰珍, 朱向东, 段永强, 等. 胃炎灵胶囊对慢性萎缩性胃炎模型大鼠血清SOD活性和MDA含量及胃黏膜组织形态的影响[J]. 中医药学报, 2007, 35(4):23-25. [6] Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom Helicobacter pylori Was Eradicated[J]. Gastroenterology, 2001, 120(5):380-386. [7] 吕宾, 王慧萍, 陈明涛, 等. 根除幽门螺杆菌对胃黏膜萎缩和肠化影响的随访研究[J]. 中华内科杂志, 2004, 43(4):299-301. [8] Kilciler G, Polat Z, Uygun A, et al. The Efect of Helicobacter Pylori Eradication on Atrophic Gastritis and Intestinal metaplasia[J]. Journal of Clinical & Analytical Medicine, 2011, 2(1):17-20. [9] Hojo M, Miwa H, Ohkusa T, et al. Alteration of histological gastritis after cure of Helicobacter pylori infection [J]. Alimentary Pharmacology & Therapeutics, 2002, 16(11):1923–1932. [10] Correa P, Fontham E T H, Bravo J C, et al. Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy[J]. Journal of the National Cancer Institute, 2000, 92(23):1881. [11] 李军祥, 陈誩, 吕宾, 等. 慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2):121-131. [12] Tang XD, Zhou LY, Zhang ST, et al. Randomized double-blind clinical trial of Moluodan, for the treatment of chronic atrophic gastritis with dysplasia.[J]. Chinese Journal of Integrative Medicine, 2016, 22(1):9-18. [13] 王灵宝. 叶酸联合摩罗丹治疗慢性萎缩性胃炎的效果观察. 中国当代医药, 2015, 22(17): 137-139. [14] 师耀美, 付卿业. 叶酸联合摩罗丹治疗慢性萎缩性胃炎的效果探讨. 北方医药, 2017, 14(1): 91-92. [15] 黄子杰, 周忠杰, 周颖, 等. 摩罗丹联合硒酵母治疗Hp阳性慢性萎缩性胃炎随机平行对照研究[J]. 实用中医内科杂志, 2013(2s): 89-91. |
|
|
